THIS LETTER IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

Advanced Medical Solutions Group plc
Premier Park
33 Road One
Winsford Industrial Estate
Winsford
Chesire
CW7 3RT

20 July 2026

*To the holders of options granted under the Advanced Medical Solutions Group plc Share Option Plan 2019 (**GSOP**), the Advanced Medical Solutions Group plc 2010 Company Share Option Plan (**CSOP**) and the Advanced Medical Solutions Group plc Executive Share Option Scheme (**ESOS**) (together, the **Plans**) which have an exercise price which is greater than 285 pence per AMS Share*

Dear Participant

Recommended cash acquisition of Advanced Medical Solutions Group plc (AMS) by H.B. Fuller Medical Adhesive Technologies Inc. (Bidco), a wholly-owned subsidiary of H.B. Fuller Company (H.B. Fuller): How it affects your 'underwater' options under the Plans

Introduction

On 25 June 2026, the boards of directors of AMS and H.B Fuller announced that they had reached agreement on the terms of a recommended cash acquisition of the entire issued and to be issued ordinary share capital of AMS by Bidco (the **Acquisition**). The Acquisition is expected to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act.

This Letter tells you about the impact of the Acquisition on the options you hold under the Plans which have an exercise price which is greater than 285 pence per AMS Share (**Options**) and the decisions you are able to make.

Please read everything in this Letter and its appendices carefully. **Their contents are very important.**

You will find a list of definitions in **Appendix A,** which explain the key defined terms used in this Letter. Any capitalised terms not included in Appendix A have the meaning given to them in the Scheme Document.

Your Options

You are receiving this Letter because you hold one or more Options which are 'underwater' (i.e. the exercise price of the Option is more than 285 pence per AMS Share). If you hold other options granted under the Plans which have an exercise price which is less than 285 pence per AMS Share or awards granted under any other AMS share plan, you will receive a separate communication. Please also read any such other communication carefully as the treatment of those options or awards is different from the treatment of the Options.

Your Options are currently exercisable and, in consequence of the Acquisition, they will remain exercisable until a specific date after completion of the Acquisition following which they will lapse. That date will be 20 days after the Effective Date (in the case of qualifying Options granted under the Schedule of the GSOP), one month after the Sanction Hearing (in the case of Options under the CSOP and non-qualifying Options under the GSOP), or three months after the Sanction Hearing (in the case of Options under the ESOS).

However, the exercise price of each of your Options is significantly in excess of the Consideration of 285 pence per AMS Share receivable by AMS Shareholders under the Acquisition. If you were to exercise any of your Options, you would need to pay more to exercise the Option than the value of the Consideration you would receive from the disposal of the AMS Shares you acquire from that Option. Therefore, it has been assumed that you would not choose to exercise any of your Options as there would be no economic advantage for you to do so. In this context, no proposals are required to be made by Bidco to you in relation to your Options.

If, for any reason, you do wish to exercise your Options, please contact [redacted] as soon as possible, in order to allow you to take any required action (including payment of the relevant exercise price). If you exercise your Options and you retain any resulting AMS Shares until the Scheme Record Time, they will be automatically transferred to Bidco under the Scheme on the Effective Date.

Questions

If you have any questions on the contents of this Letter, please contact [redacted]. However, please be aware that no legal, tax, financial or investment advice on the Acquisition or its effect on your Options can be provided by AMS or Bidco. **If you are in any doubt as to the action you should take, you should seek your own independent professional advice.**

Yours faithfully

[redacted]

For and on behalf of:
Advanced Medical Solutions Group plc

ACQUISITION SUMMARY

1. How does the Acquisition work?

The Acquisition will result in AMS and its subsidiaries becoming wholly-owned subsidiaries of Bidco (or its nominee).

The Acquisition will be carried out through what is called a "scheme of arrangement". This is a procedure that has to be first approved by AMS Shareholders at a shareholder meeting, to be held on 12 August 2026 and then approved by the Court at the Sanction Hearing (see paragraph 3 below). This is not the date on which the Acquisition will be completed. The Acquisition is currently due to complete two business days after the Sanction Hearing when the Scheme becomes effective. If you want to read more about this, please go to the AMS website (at www.admedsol.com), where you will find the Scheme Document that was sent to AMS Shareholders on or around the date of this Letter as well as a copy of this Letter.

2. What can AMS Shareholders receive under the Acquisition?

The terms of the Acquisition are set out in full in the Scheme Document. However, in summary (and subject to the terms of the Acquisition), an AMS Shareholder will be entitled to receive 285 pence in cash for each AMS Share they hold at the Scheme Record Time.

Any AMS Share allotted and issued to any person after the Scheme Record Time to satisfy the vesting or exercise of any award under the AMS Share Plans will be immediately transferred to Bidco (and/or such other nominee(s) of Bidco as it may direct) on the Effective Date or, if later, on issue in exchange for the provision by Bidco of the Consideration.

3. When will the Acquisition take place?

The date of the Sanction Hearing is still to be confirmed, but it is expected to be in the third or fourth quarter of 2026, subject to AMS Shareholder approval and the satisfaction of the remaining conditions to the Scheme. An expected timeline of key events relating to the Acquisition is available in the Scheme Document, and you will be notified of any changes to this timeline which affect you.

Once the date of the Sanction Hearing is confirmed, AMS will announce this via a Regulatory Information Service (with the announcement being made available on AMS's website at www.admedsol.com).

4. Will the Acquisition definitely go ahead?

The Acquisition is conditional on various approvals and consents including: (i) approval by AMS Shareholders at a meeting to be held on 12 August 2026; (ii) the satisfaction of certain other conditions to the Scheme (including regulatory clearances); and (iii) the sanction of the Court. You should note that there is no certainty that AMS Shareholders will approve the Acquisition and/or that the Court will sanction the Scheme.

5. What if the Acquisition does not go ahead?

If the Court does not sanction the Scheme at the Sanction Hearing, your Options will continue as normal under the rules of the relevant Plan.

NOTES:

(a) The release, publication or distribution of this Letter and/or any accompanying documents (in whole or in part) in, into or from jurisdictions other than the United Kingdom may be restricted by the laws of those jurisdictions and therefore persons into whose possession this Letter comes should inform themselves about, and observe, any such restrictions. Failure to comply with any such restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by law, AMS and Bidco disclaim any responsibility or liability for the violation of such restrictions by such persons.

(b) The AMS Directors, whose names are set out in paragraph 2.1 of Part VI of the Scheme Document, accept responsibility for the information contained in this Letter (including any expressions of opinion). To the best of the knowledge and belief of the AMS Directors (having taken all reasonable care to ensure that such is the case), the information contained in this Letter for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

(c) Accidental omission to despatch this letter to, or any failure to receive the same by, any person to whom this letter should be sent shall not invalidate the contents of this Letter in any way.

(d) In the event of any conflict between this Letter and the rules of the Plans and the applicable legislation, the rules of the Plans and the applicable legislation take precedence.

(e) The terms set out in this Letter shall be governed by and construed in accordance with English law.

Appendix A

Defined Terms

AMS	Advanced Medical Solutions Group plc, a public limited company incorporated and registered in England and Wales with registered number 02867684
AMS Shareholders	holders of AMS Shares
AMS Shares	the ordinary shares of 5 pence each in the capital of AMS
Bidco	H.B. Fuller Medical Adhesive Technologies Inc., a corporation incorporated in Delaware (registered number 5560413) and whose principal place of business is at 1200 Willow Lake Boulevard, St. Paul, MN. USA
Consideration	285 pence payable by Bidco in cash for each Scheme Share
Court	the High Court of Justice in England and Wales
CSOP	the Advanced Medical Solutions Group plc 2010 Company Share Option Plan
ESOS	the Advanced Medical Solutions Group plc Executive Share Option Scheme
Effective Date	the date on which the Acquisition becomes effective in accordance with its terms
GSOP	the Advanced Medical Solutions Group plc Share Option Plan 2019
Letter	this letter from AMS and Bidco explaining the impact of the Acquisition on the Options
Option	an option to acquire AMS Shares granted under the Plans which has an exercise price which is greater than 285 pence per AMS Share
Plans	the CSOP, the ESOS and the GSOP
Sanction Hearing	the hearing of the Court at which the order of the Court sanctioning the Scheme under Part 26 of the Companies Act will be sought, including any adjournments thereof

Scheme	the proposed scheme of arrangement to be made under Part 26 of the Companies Act between AMS and the Scheme Shareholders with or subject to any modification, addition or condition approved or imposed by the Court (where relevant) and agreed to by AMS and Bidco, as set out in Part IV (The Scheme of Arrangement) of this document
Scheme Document	the document dated on or around the date of this Letter addressed to AMS Shareholders, of which the Scheme forms part
Scheme Record Time	6.00 p.m. on the Business Day immediately preceding the Effective Date or such other date and/or time as AMS and Bidco may agree